Search results for "Hepatitis B Antigens"

showing 8 items of 18 documents

The diagnostic significance of intrahepatocellular hepatitis-B-surface-antigen (HB s Ag), hepatitis-B-core-antigen (HB c Ag) and IgG for the classifi…

1975

Liver biopsies of patients with inflammatory liver diseases and clinically healthy HBsAg-carriers were examined for presence of intracellular HBsAg, HBcAg and IgG by direct immunofluorescence. The studies revealed the following results: 1. In most cases healthy HBsAg-carriers had HBsAg in the cytoplasm, but they did never show HBcAg in the nuclei of hepatocytes. 2. In the early phase some patients with HBsAg-positive acute hepatitis had HBcAg and/or HBsAg in their hepatocytes. In a normal course with complete recovery the immunoelimination may clear either phenomenon at variable stages of the disease. 3. Cases one year after complete recovery of acute virus B-hepatitis had no HB-components …

HBsAgVirusHepatitis B AntigensAntigenDrug DiscoverymedicineHumansDirect fluorescent antibodyGenetics (clinical)Cell NucleusHepatitismedicine.diagnostic_testbusiness.industryLiver cellvirus diseasesGeneral MedicineHepatitis Amedicine.diseasedigestive system diseasesHBcAgLiverVirus DiseasesImmunoglobulin GLiver biopsyAcute DiseaseCarrier StateChronic DiseaseImmunologyMolecular MedicinebusinessKlinische Wochenschrift
researchProduct

Glomerulonephritis und Hepatitis-B-Virus-Infektion

1990

Hepatitis B AntigensGlomerulonephritisbusiness.industryHumansMedicineGeneral MedicineHepatitis BPrognosisbusinessPolyarteritis NodosaDMW - Deutsche Medizinische Wochenschrift
researchProduct

Treatment options in HBV.

2005

The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18). HBeAg positive patients with normal or slightly raised ALT should be treated only if there is histological evidence of progressive disease. In patients with HBeAg negative chronic hepatitis, less than 20% of subjects who have achieved an end-of-treatment virological response after a course of standard IFN maintain a sustained virological response in the long-term. IFN tre…

Hepatitis B virusHBsAgmedicine.medical_specialtyAdefovirmedicine.disease_causeAntiviral AgentsGastroenterologyHepatitis B AntigensLiver diseaseInternal medicineAdefovirHumansMedicineHepatitis B virusHepatologybusiness.industryvirus diseasesLamivudineHIVHepatitis Bmedicine.diseaseHepatitis Bdigestive system diseasesTreatmentTreatment OutcomeHBeAgLamivudineDNA ViralImmunologyNumber needed to treatInterferonbusinessLiver diseasemedicine.drug
researchProduct

From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005).

2006

Hepatitis B virus infection, which was for over a decade put aside by the rising star of hepatitis C, has seen over the last years a resurgence of interest. This stemmed from a better knowledge of the virus itself, from the availability of new drugs and combinations, and from the realization that far from being eradicated by mass immunization programs HBV is still on a worldwide basis the major cause of cirrhosis and hepatocellular carcinoma, alone or in combinations with other viruses, alcohol andmetabolic cofactors. This prompted the EASL Scientific Committee to organize a Monothematic Conference on HBV. Experts from Europe, USA, Canada, Australia, the Far East and other parts of the worl…

Hepatitis B virusmedicine.medical_specialtyHepatitis B virusHepatologybusiness.industryIstanbul turkeyhepatitis B viruHepatitis Chepatocellular carcinomamedicine.disease_causemedicine.diseaseHepatitis BVirologyHepatitis B AntigensMass immunizationChronic hepatitischronic hepatitiFamily medicinemedicineHumansViremiabusinesscirrhosiJournal of hepatology
researchProduct

e System and intrahepatocelullar HBcAG and HBsAG in HBsAG positive patients with liver diseases and healthy carriers.

1977

Patients with hepatitis-B surface antigen positive liver diseases and healthy carriers were studied for the presence of e-antigen and anti-e as well as for intrahepatocellular HBsAG and hepatitis-B core antigen. The e-antigen was demonstrated in 9 out of 12 patients with chronic perisitent hepatitis, in 15 out of 39 patients with chronic active hepatitis, in 3 out of 40 patients with acute type B hepatitis, and in 2 out of 9 patients with a protracted course of type B hepatitis. No e-antigen was found in healthy HBsAG carriers nor in patients with complete recovery from type B hepatitis one year after onset of the disease. Anti-e was detected in 24 out of 61 healthy HBsAG carriers with a no…

HepatitisHBsAgChronic Activebusiness.industryLiver cellLiver DiseasesGastroenterologyChronic persistent hepatitisDiseasemedicine.diseaseHepatitis BHepatitis B Core AntigensHepatitisHepatitis B AntigensHBcAgAntigenLiverImmunologyAcute DiseaseCarrier StateChronic DiseasemedicineHumansAntigensbusinessScandinavian journal of gastroenterology
researchProduct

A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis.

1985

The prevalence of intrahepatic delta antigen and/or anti-delta antibody was retrospectively investigated in 102 children with chronic HBsAg-positive hepatitis who were seen consecutively in three medical institutions between 1974 and 1982. Delta infection markers were found in 13 patients (12.7%) who exhibited high serum titers of anti-delta antibody; intrahepatic delta antigen was detected in ten. Eleven of the 13 children had severe progressive liver disease associated in all but one with absence of hepatitis B virus replication as evaluated by analysis of serum hepatitis B virus DNA. The factors which seem to increase the risk of delta infection in children who are hepatitis B virus carr…

MaleHBsAgCirrhosisAdolescentmedicine.disease_causeChronic liver diseaseHepatitisHepatitis B AntigensmedicineHumansChildRetrospective StudiesHepatitis B virusHepatitisHepatitis delta AntigensHepatitis B Surface AntigensHepatologybiologyChronic Activebusiness.industryInfantHepatitis delta Antigensmedicine.diseaseChild PreschoolImmunologyChronic Diseasebiology.proteinFemaleAntibodybusinessHepatology (Baltimore, Md.)
researchProduct

ABO blood groups and Australia antigen

2008

The distribution of ABO blood in two groups of people with Australia antigen was studied (121 blood donors and 128 patients) and in 3,091 controls was investigated. There was a significant excess of A in comparison with o when the two groups were combined, and when the two groups were tested for (A + B): (AB +O) individually and together, both were found to be statistically significant. The results are discussed.

business.industryComplement Fixation TestsGenetic Complementation TestBlood DonorsHepatitis B AntigensABO Blood-Group SystemHepatitisHepatitis B AntigensGenetics PopulationPhenotypeAntigenABO blood group systemImmunologyMethodsGeneticsHumansMedicinebusinessGenetics (clinical)Clinical Genetics
researchProduct

Hepatitis B virus in diabetic patients

1980

The presence of HBV markers was determined in 149 serum samples obtained from diabetic patients and was compared with a normal population. Diabetics have the same incidence of HBsAg but significantly higher anti-HBc antibodies. These differences were seen in the group of diabetics on oral hypoglycemic therapy. These results cannot yet be explained.

medicine.medical_specialtyHBsAgEndocrinology Diabetes and MetabolismHbv markersAntibodies Viralmedicine.disease_causeGastroenterologyHepatitis B AntigensEndocrinologyInternal medicineDiabetes mellitusEpidemiologyDiabetes MellitusInternal MedicinemedicineHumansHepatitis B AntibodiesHepatitis B virusbiologybusiness.industryIncidence (epidemiology)virus diseasesGeneral MedicineSerum samplesmedicine.diseasedigestive system diseasesImmunologybiology.proteinAntibodybusinessActa Diabetologica Latina
researchProduct